Overactive Bladder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 128 pages | ID: OADB7C66956CEN
Global Markets Direct

Abstracts

Overactive Bladder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Drugs In Development, 2022, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 2, 4, 4, 10, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Overactive Bladder - Overview
Overactive Bladder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Overactive Bladder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Overactive Bladder - Companies Involved in Therapeutics Development
Overactive Bladder - Drug Profiles
Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones
Featured News & Press Releases
May 15, 2022: Urovant Sciences presents new data from EMPOWUR study, advancing knowledge of the treatment of overactive bladder at the 2022 American Urological Association Meeting
May 13, 2022: Urovant Sciences presents interim data from phase 2a study of investigational novel gene therapy, URO-902, supporting safety, tolerability, and efficacy endpoints at 2022 American Urological Association Meeting
Apr 19, 2022: Urovant sciences announces publication of EMPOWUR trial subgroup analysis showing similar efficacy for GEMTESA in dry and wet overactive bladder populations
Apr 13, 2022: Urovant Sciences to present new analyses of data from phase 3 EMPOWUR extension trial of GEMTESA (vibegron) 75 mg at 2022 American Urological Association Annual Meeting
Apr 13, 2022: Urovant Sciences to present interim data from phase 2a study of potential novel gene therapy, URO-902 at 2022 American Urological Association Annual Meeting
Mar 25, 2022: Jeil applies for product permit for new overactive bladder treatment
Mar 21, 2022: Urovant Sciences announces publication of new review of efficacy and safety data for GEMTESA (vibegron) 75 mg in overactive bladder patients in the Journal Therapeutics and Clinical Risk Management
Mar 07, 2022: Urovant Sciences announces positive topline results of phase 2a trial of its potential novel gene therapy, URO-902
Dec 20, 2021: Urovant Sciences announces publication in Advances in Therapy of analyses of patient-perceived meaningfulness of improvement in symptom reduction for overactive bladder patients treated with GEMTESA (vibegron) 75 mg
Nov 08, 2021: Urovant Sciences announces publication in Blood Pressure Monitoring of positive ambulatory blood pressure study results for GEMTESA (vibegron) 75 mg in overactive bladder patients
Sep 13, 2021: Urovant Sciences presents positive ambulatory blood pressure data showing that GEMTESA (vibegron) 75 mg in overactive bladder was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate
Sep 03, 2021: Urovant Sciences to present new ambulatory blood pressure data in patients dosed with GEMTESA (vibegron) 75 mg for overactive bladder at the virtual 2021 annual meeting of the American Urological Association
Aug 18, 2021: Urovant Sciences to present new ambulatory blood pressure data in patients dosed with GEMTESA (vibegron) 75 mg for overactive bladder at the 2021 Annual Meeting of the American Urological Association
Jun 29, 2021: Urovant Sciences and Sunovion Pharmaceuticals launch primary care co-promotion of GEMTESA (vibegron) for patients with overactive bladder
Apr 15, 2021: Urovant Sciences announces publication of positive long-term clinical safety and efficacy data on the FDA-approved overactive bladder therapy, GEMTESA (vibegron), in the Journal of Urology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Overactive Bladder, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Overactive Bladder - Pipeline by Aardvark Therapeutics Inc, 2022
Overactive Bladder - Pipeline by Aetas Pharma Co Ltd, 2022
Overactive Bladder - Pipeline by Astellas Pharma Inc, 2022
Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, 2022
Overactive Bladder - Pipeline by Dong-A ST Co Ltd, 2022
Overactive Bladder - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Overactive Bladder - Pipeline by Exxel Pharma Inc, 2022
Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Overactive Bladder - Pipeline by Hetero Drugs Ltd, 2022
Overactive Bladder - Pipeline by Imbrium Therapeutics LP, 2022
Overactive Bladder - Pipeline by Johnson & Johnson, 2022
Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Overactive Bladder - Pipeline by Korea United Pharm Inc, 2022
Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, 2022
Overactive Bladder - Pipeline by Merck & Co Inc, 2022
Overactive Bladder - Pipeline by Pantherics Inc, 2022
Overactive Bladder - Pipeline by PeLeMed Co Ltd, 2022
Overactive Bladder - Pipeline by Recordati SpA, 2022
Overactive Bladder - Pipeline by Revance Therapeutics Inc, 2022
Overactive Bladder - Pipeline by Sea4Us - Biotecnologia e Recursos Marinhos Lda, 2022
Overactive Bladder - Pipeline by Sinsin Pharmaceutical Co Ltd, 2022
Overactive Bladder - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Overactive Bladder - Pipeline by TheraVida Inc, 2022
Overactive Bladder - Pipeline by Urovant Sciences Inc, 2022
Overactive Bladder - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
Overactive Bladder - Dormant Projects, 2022
Overactive Bladder - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Overactive Bladder, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022